Telehealth ADHD Prescribing: What PMHNPs Can Do in California

You’re a psychiatrist with DEA registration, board certification, and years of experience managing ADHD patients. A telehealth platform recruits you to see patients online. One question keeps coming up: Can I legally prescribe Adderall and other stimulants through video visits?

The short answer in 2026: Yes, but the rules are in flux.

Federal telehealth flexibilities that allowed psychiatrists to prescribe Schedule II stimulants without an initial in-person exam have been extended through December 31, 2025 — and we’re now in early 2026 with no permanent rule in place. State laws add another layer. Some states explicitly welcome telehealth ADHD prescribing. Others impose restrictions that don’t exist for in-person care.

If you’re considering joining a telehealth platform or expanding your virtual practice to treat ADHD, here’s what you need to know about prescribing stimulants online, state-by-state scope differences, reimbursement realities, and how to stay compliant while meeting massive patient demand.

The Federal Framework: Ryan Haight Act and COVID-Era Waivers

Before COVID-19, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 required at least one in-person medical evaluation before a provider could prescribe any Schedule II controlled substance via telemedicine. That meant even a video visit wasn’t sufficient — you had to see the patient face-to-face at least once.

The pandemic changed everything. In March 2020, the DEA issued an emergency waiver allowing providers to prescribe controlled substances, including ADHD stimulants, entirely via telehealth without that initial in-person visit. This waiver was supposed to end when the Public Health Emergency concluded in May 2023.

Instead, the DEA extended it multiple times. The most recent extension, announced in November 2024, pushed the deadline to December 31, 2025. This means throughout 2024 and 2025, psychiatrists could legally initiate Adderall, Ritalin, Vyvanse, and other Schedule II stimulants through telehealth alone, assuming they conducted a proper evaluation via audio-video and maintained standard of care.

Where does that leave us in early 2026? As of now, there’s no permanent federal rule. Congress has debated legislation to make telehealth prescribing permanent or create a special DEA registration for telemedicine providers, but nothing has passed. If the waiver isn’t extended again and no new rule is implemented, we could revert to the Ryan Haight Act’s in-person requirement.

Practical takeaway for psychiatrists: You can prescribe ADHD stimulants via telehealth today under the extended federal flexibility. But build contingency plans — partner with local clinics for in-person exams if needed, or prepare to adjust your practice model if the law changes mid-2026.

The DEA has floated a ‘special registration’ pathway for telemedicine prescribing of controlled substances, which could allow providers who meet certain standards to prescribe Schedule II drugs online permanently. Watch for rulemaking in 2026. Until then, we’re operating in an extended grace period.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Telehealth Laws: Why Your License State Matters

Federal law sets the floor, but states can add requirements. Some states have been proactive in codifying telehealth prescribing rules, especially for mental health. Others remain silent, defaulting to federal guidelines.

Florida: Explicitly Permits Telehealth Stimulant Prescribing for Psychiatric Disorders

Florida Statute 456.47 generally restricts prescribing Schedule II controlled substances via telehealth — except when the drug is prescribed for psychiatric disorders, inpatient hospital treatment, hospice, or nursing home care. ADHD qualifies as a psychiatric disorder, so a Florida-licensed psychiatrist can prescribe stimulants through telehealth legally under state law.

This is a significant carve-out. While Florida limits telehealth prescribing of Schedule II opioids (to combat pill mills), it recognizes the legitimacy of telepsychiatry for ADHD. Florida also requires providers to meet the same standard of care as in-person visits — meaning thorough evaluations, proper documentation, and follow-up monitoring.

Florida’s PDMP requirement: You must check the state’s Prescription Drug Monitoring Program (E-FORCSE) before prescribing controlled substances. Most telehealth platforms integrate PDMP checks into their workflows, but it’s your responsibility to verify.

Texas: Telemedicine Allowed for Mental Health, But Watch NP Restrictions

Texas allows telehealth prescribing of controlled substances for mental health conditions (not chronic pain, which is explicitly restricted). A psychiatrist in Texas can conduct a live audio-video evaluation and prescribe stimulants for ADHD without violating state law.

However, Texas has strict rules for Nurse Practitioners: NPs in Texas cannot prescribe Schedule II controlled substances for routine outpatient care. Only physicians can write those prescriptions. If you’re a psychiatrist overseeing NPs on a telehealth platform, you’ll need to handle all stimulant prescriptions yourself or structure collaborative agreements carefully.

Texas also prohibits audio-only controlled substance prescribing (with rare exceptions). You must use video. And while stimulants aren’t on the mandatory PDMP check list in Texas (unlike opioids and benzodiazepines), checking the Prescription Monitoring Program is still best practice.

New York: No Additional State Barriers, But Strict E-Prescribing and PDMP Rules

New York doesn’t impose telehealth-specific restrictions on controlled substances beyond federal law. A New York-licensed psychiatrist following the federal waiver can prescribe ADHD meds via telehealth.

However, New York has strict compliance requirements:

• Mandatory e-prescribing: Since 2016, all prescriptions in New York — including controlled substances — must be transmitted electronically. Paper prescriptions for Adderall are essentially banned except in rare circumstances.
• I-STOP/PDMP checks required: You must consult the New York Prescription Monitoring Program before prescribing any Schedule II, III, or IV controlled substance. This isn’t optional. Document each PDMP check in the patient’s record.

New York’s telehealth environment is otherwise favorable. The state enacted payment parity laws requiring insurers to reimburse telehealth visits at the same rate as in-person. Medicaid covers tele-mental health, including audio-only for some services (though video is preferred for controlled substances).

Pennsylvania: Follows Federal Law, But Adds NP Prescribing Limits

Pennsylvania doesn’t have a state law explicitly addressing telehealth prescribing of controlled substances for psychiatry. You follow federal guidelines — which currently allow it under the DEA waiver.

Pennsylvania’s wrinkle is for Nurse Practitioners: NPs in PA can only prescribe an initial Schedule II prescription for 72 hours and must notify their collaborating physician. Ongoing prescriptions are limited to 30-day supplies. This doesn’t affect psychiatrists directly, but if you’re supervising NPs, you’ll need to be involved early in the patient’s treatment.

Pennsylvania has strong telehealth adoption. Most insurers cover telepsychiatry at parity, and the state’s Medicaid program reimburses video and audio visits for mental health.

Illinois: Telehealth-Friendly, NPs Gaining Independence

Illinois allows telehealth prescribing of controlled substances with no additional state restrictions beyond federal law. Illinois also has a progressive stance on NP practice: experienced Psychiatric Nurse Practitioners (after 4,000 clinical hours and additional training) can obtain Full Practice Authority and prescribe Schedule II stimulants independently.

For psychiatrists, this means if you’re collaborating with NPs in Illinois, experienced NPs can share the prescribing load without constant oversight. Illinois also mandates e-prescribing for all controlled substances as of 2023 and requires PDMP checks (though not as strictly as New York).

Illinois enacted telehealth payment parity, so reimbursement is solid. Chicago has a high concentration of providers, but downstate Illinois has severe shortages — telehealth is filling critical gaps.

California: Transitioning to NP Independence, Strong Telehealth Support

California follows federal law on telehealth controlled substance prescribing. No additional state barriers for psychiatrists.

California’s nursing practice act is evolving: under AB 890, experienced NPs (≥3 years, 4,600 hours) can apply for independent practice status (‘104 NPs’). Until then, they need physician supervision. California also requires NPs to complete a special pharmacology course to prescribe Schedule II drugs.

California mandates e-prescribing for controlled substances (implemented in 2022). All stimulant prescriptions must go through an EPCS-compliant system. California also has strong telehealth parity laws, ensuring you’re paid fairly for virtual visits.

What Psychiatrists Can Do (That NPs Often Can’t)

One major advantage psychiatrists have over other providers: unrestricted prescriptive authority in every state.

Psychiatric Nurse Practitioners face a patchwork of scope-of-practice laws. In Texas and Florida, NPs need physician oversight and face strict limits on Schedule II prescribing (Texas NPs can’t prescribe stimulants for outpatient ADHD at all). In Pennsylvania, NPs can only prescribe 72 hours of a Schedule II initially. Even in progressive states like New York and Illinois, NPs need experience and collaboration before achieving independence.

Psychiatrists don’t face any of these restrictions. If you’re licensed in a state and have a DEA registration, you can prescribe any ADHD medication without supervision, collaborative agreements, or arbitrary quantity limits (beyond standard DEA rules like 30-day supply for Schedule II).

This makes psychiatrists essential on telehealth platforms, especially in restricted-practice states. You can:

• Diagnose ADHD via comprehensive telehealth evaluation (clinical interview, rating scales, collateral information)
• Initiate stimulant therapy with appropriate dosing
• Conduct monthly follow-ups for medication management (required for ongoing Schedule II prescriptions)
• Adjust medications, coordinate with primary care for vitals monitoring, and manage side effects
• Order labs or coordinate ancillary services as needed

You can do all of this through video visits. The clinical standard is the same as in-person: document thoroughly, use validated assessment tools (ADHD Rating Scale, ASRS for adults), obtain informed consent, and monitor for misuse.

The Economics: What Telehealth ADHD Prescribing Actually Pays

Let’s talk money. Telehealth psychiatry is financially viable in 2026 thanks to widespread payment parity.

Insurance reimbursement rates:

• Medicare pays approximately $89-$95 for CPT 99213 (established patient, 15-minute med check) and $125-$136 for 99214 (25-minute visit). These are 2024-2025 fee schedule numbers, with slight regional variation.
• Commercial insurance typically pays equal to or higher than Medicare — often 10-30% more depending on the carrier and contract.
• Initial psychiatric evaluations (CPT 90792) are reimbursed around $190-$202 by Medicare, with private payers sometimes going higher.

Medicaid pays less — roughly $40-$65 for a 15-minute visit depending on the state. But nearly 48 states have enacted telehealth payment parity laws, meaning if you see a Medicaid patient via video, you’re paid the same as you would in-person.

Psychiatrists are reimbursed at the highest level among mental health providers. NPs and therapists often bill at lower rates or must meet ‘incident to’ billing requirements. Your MD/DO license commands premium reimbursement.

Volume and efficiency: Telehealth eliminates commute time, allows flexible scheduling, and often sees lower no-show rates (patients can join from home or work). If you conduct four 15-minute med checks per hour via telehealth at $90 each (conservative Medicare rate), that’s $360/hour gross revenue — comparable to or better than in-office psychiatry, with lower overhead.

ADHD medication management visits are typically brief and focused: symptom review, side effect check, refill. This is ideal for telehealth. Initial evaluations might run 45-60 minutes, but follow-ups are efficient.

The platform model: Many telehealth services operate on a hybrid model:

• Insurance-based: Provider is credentialed with major payers, bills insurance, and is reimbursed per visit (minus platform fee or revenue share).
• Cash-pay or subscription: Patients pay out-of-pocket; provider receives a negotiated rate per visit or percentage of revenue.

Klarity Health, for example, uses a pay-per-appointment model where providers are paid a standard rate per completed visit. No upfront marketing costs, no monthly subscriptions to directories, no wasted ad spend. You only pay when you see a patient, and the platform handles patient acquisition, scheduling, and billing infrastructure.

Compare that to running your own practice: acquiring a qualified psychiatric patient through DIY marketing (Google Ads, SEO, directories like Psychology Today) realistically costs $200-$500+ per patient when you account for:

• Agency or consultant fees
• Ad spend and testing ($15-40 per click for mental health keywords, most clicks don’t convert)
• Staff time to handle leads and schedule
• No-show rates from cold leads
• Months of investment before SEO generates meaningful traffic

Platforms like Klarity remove that risk. You’re guaranteed ROI: pay only when a pre-qualified, pre-matched patient books with you.

Managing ADHD via Telehealth: Clinical Workflows and Best Practices

Telehealth ADHD care isn’t a shortcut. It requires the same rigor as in-office practice — arguably more, given increased scrutiny after some online prescribing scandals.

Initial Evaluation (45-60 minutes):

• Verify patient identity and location (for licensing compliance and state law)
• Comprehensive psychiatric history: onset of symptoms, school/work functioning, previous evaluations
• Use validated screening tools: ADHD Rating Scale (children), ASRS (adults), Conners’ scales
• Rule out other conditions: anxiety, depression, bipolar, substance use (all can mimic ADHD)
• Collateral information when possible: school reports for kids, partner input for adults
• Document DSM-5 criteria: six or more symptoms of inattention/hyperactivity, present before age 12, impairing function in multiple settings
• Discuss treatment options: stimulants, non-stimulants, behavioral therapy
• Obtain informed consent covering risks (cardiovascular, misuse potential, side effects)

Prescribing Workflow:

• E-prescribe through DEA-compliant platform (two-factor authentication required)
• Start with conservative dosing: immediate-release stimulants allow flexibility; extended-release for convenience
• Check PDMP for any red flags (overlapping controlled substances, multiple prescribers)
• Coordinate with primary care for baseline vitals if indicated (blood pressure, heart rate) — some patients can self-report or use home monitors; others may need a PCP visit
• Schedule first follow-up in 1-2 weeks to assess response and side effects

Ongoing Medication Management (15-20 minutes monthly):

• Symptom review: focus, concentration, hyperactivity, impulsivity
• Side effect monitoring: appetite, sleep, mood, cardiovascular symptoms
• Adherence check: Are they taking meds as prescribed? Any barriers?
• Refill prescription (Schedule II = no refills, must be a new prescription each month)
• PDMP check at least every 90 days, more often if concerns arise
• Adjust dose or switch medications as needed

Red flags and safeguards:

• Early refill requests (possible misuse or diversion)
• Multiple ‘lost’ prescriptions
• Escalating doses without symptom improvement
• Substance use issues
• Erratic behavior or mood swings (stimulants can worsen mania or psychosis)

If red flags appear, consider urine drug screens, more frequent visits, or discontinuing stimulants in favor of non-stimulant options (atomoxetine, viloxazine, bupropion). Document everything.

Some patients genuinely need higher doses or more frequent adjustments. Clinical judgment matters. The key is demonstrating thoughtful, evidence-based prescribing — not reflexive denials or rubber-stamping refills.

The Reality of ADHD Demand and Medication Shortages

ADHD providers in 2026 are navigating unprecedented demand and supply challenges.

Demand surge: Stimulant prescriptions jumped significantly during the pandemic as more adults sought diagnosis and treatment. The ease of telehealth lowered barriers — patients who previously couldn’t take time off work or travel to see a psychiatrist could now access care online. Adult ADHD diagnoses skyrocketed in 2020-2022, and that demand hasn’t slowed.

Medication shortages: Starting in late 2022, shortages of Adderall and other amphetamine-based stimulants became widespread. The DEA sets annual manufacturing quotas for controlled substances, and demand outpaced supply. Patients faced pharmacy-to-pharmacy searches trying to fill prescriptions. Some shortages persist in 2026.

The DEA has increased production limits in response, but shortages still flare up periodically. This puts providers in a difficult position: prescribing appropriately, but knowing the patient may struggle to fill the prescription.

Practical strategies:

• Prescribe generics when possible (brand shortages are often worse)
• Consider methylphenidate-based stimulants (Ritalin, Concerta) as alternatives to amphetamines
• Have non-stimulant options ready: atomoxetine, viloxazine, bupropion, guanfacine, clonidine
• Maintain a list of pharmacies with better supply (though this varies constantly)
• Communicate openly with patients about shortages so they don’t blame you

Shortages aren’t a reason to stop treating ADHD, but they add complexity. Factor this into your workflow and patient counseling.

Addressing the ‘Pill Mill’ Stigma: Why Quality Matters

High-profile cases of telehealth companies inappropriately prescribing stimulants have cast a shadow over legitimate online ADHD care.

In 2023, investigations revealed some platforms were prescribing Adderall after brief text message exchanges — no video evaluation, minimal clinical assessment. This led to regulatory crackdowns, lawsuits, and Congressional scrutiny. The founder of Done Health, a major telehealth ADHD service, was indicted in 2024 for allegedly running an illegal prescription scheme.

These abuses fueled the perception that ‘online ADHD care = pill mill.’ That’s unfair to the thousands of psychiatrists practicing high-quality telepsychiatry, but the stigma exists.

How to protect yourself and your patients:

• Conduct thorough evaluations. Don’t shortcut the diagnostic process because it’s telehealth. Video allows you to observe the patient, review records, use structured assessments.
• Document rigorously. If audited, your notes should demonstrate you met the standard of care: history, mental status exam, differential diagnosis, rationale for prescribing.
• Follow up regularly. Monthly visits for stimulants aren’t just good medicine — they’re documentation that you’re monitoring appropriately.
• Use clinical judgment on dose escalation. If a patient keeps asking for higher doses without symptom improvement, that’s a red flag. Be willing to say no.
• Coordinate with other providers. If a patient has a PCP or therapist, loop them in (with consent). Collaborative care reduces risk.

State medical boards are watching. Texas specifically flagged concerns about telehealth overprescribing in legislative discussions. Florida’s Board of Medicine has sanctioned physicians for inappropriate controlled substance prescribing. Practicing conservatively and documenting defensively isn’t just ethical — it protects your license.

Why Psychiatrists Are in High Demand (And Short Supply)

The psychiatrist workforce shortage is severe, and telehealth can’t fully solve it — but it helps.

State-by-state supply:

• Texas and Florida have some of the worst psychiatrist-to-population ratios in the country: roughly 1 psychiatrist per 9,000 residents. Many rural counties have zero psychiatrists.
• Pennsylvania and Illinois are moderate, around 1:4,600 in PA and 1:5,800 in IL. Urban areas are better served; rural regions struggle.
• California has about 1:5,000, which sounds reasonable until you consider California’s size and regional disparities (Central Valley and rural areas are shortage zones).
• New York has the best ratio, around 1:2,900, thanks to NYC’s density of providers. But upstate New York and rural counties still face access gaps.

Telehealth allows a psychiatrist in NYC to see patients in upstate New York or a Dallas-based psychiatrist to serve rural West Texas. It doesn’t solve everything — licensure still limits cross-state practice — but it extends reach within a state.

Why psychiatrists specifically? In restricted-practice states like Texas and Florida, only psychiatrists can independently prescribe ADHD stimulants. NPs can handle therapy or non-stimulant meds, but they can’t carry the caseload alone. This makes psychiatrists irreplaceable in those markets.

Even in NP-friendly states, the complexity of ADHD — especially with comorbidities (anxiety, depression, bipolar, substance use) — often requires a psychiatrist’s expertise. Telepsychiatry platforms need board-certified psychiatrists to provide safe, effective care.

For you, that means leverage. Demand is high, supply is low, and your skillset is valued. Platforms like Klarity Health actively recruit psychiatrists because patient demand far exceeds provider availability.

Joining a Telehealth Platform: What to Look For

If you’re considering telehealth ADHD work, evaluate platforms on these factors:

1. Patient acquisition and quality:Does the platform market effectively and pre-qualify patients? You don’t want to spend half your visit explaining what ADHD is or convincing someone they need treatment. Platforms that screen patients (structured intake forms, symptom questionnaires) save you time.

2. Compensation model:

• Pay-per-visit (flat rate per appointment)
• Revenue share (you get a percentage of what the patient pays)
• Salary or hourly rate

Understand the economics. On a pay-per-visit model, higher patient volume = higher income, but you need efficient workflows. Revenue share aligns incentives but can be unpredictable.

3. Licensing and credentialing support:Does the platform help with multi-state licensing (if you want to expand)? Do they credential you with insurers, or is that your responsibility?

4. Technology and compliance:

• EPCS-compliant e-prescribing
• Integrated PDMP checks
• HIPAA-secure video platform
• EHR with good documentation templates

You need tools that make prescribing controlled substances straightforward and compliant. If you’re manually checking the PDMP in a separate browser and copying notes into a clunky EHR, your efficiency tanks.

5. Clinical autonomy:Can you set your own schedule? Choose which patients to see? Decline cases that don’t fit your comfort zone? Some platforms give providers full control; others have rigid protocols.

6. Malpractice coverage:Does the platform provide malpractice insurance, or do you need your own? Make sure telehealth is covered.

7. Revenue vs risk:A platform that removes marketing costs and patient acquisition risk — where you only pay when you see a patient — offers better ROI than investing thousands per month in ads and hoping patients show up. Klarity Health’s model, for instance, eliminates upfront costs: you’re paid per completed visit, the platform handles intake and scheduling, and you don’t gamble on marketing channels.

Compare that to spending $3,000-5,000/month on a mix of SEO, Google Ads, and directory listings, waiting 6-12 months for results, and dealing with no-shows from cold leads. The platform model is lower risk, faster ramp-up.

FAQ: Telehealth ADHD Prescribing for Psychiatrists

Can I prescribe Adderall via telehealth in 2026?

Yes, under current federal policy. The DEA extended COVID-era flexibilities through December 31, 2025, and there’s no permanent rule yet as of early 2026. State laws vary, but psychiatrists can generally prescribe stimulants via telehealth in states like Florida (explicitly allowed for psychiatric disorders), Texas (allowed for mental health), New York, Pennsylvania, Illinois, and California, provided you follow federal guidelines and conduct proper evaluations.

Do I need an in-person exam before prescribing stimulants via telehealth?

Not currently. The Ryan Haight Act’s in-person requirement is waived under the DEA’s temporary extension. If that waiver expires without replacement, an in-person exam would be required again. Monitor DEA rulemaking in 2026.

What states restrict NP prescribing of ADHD meds?

Texas prohibits NPs from prescribing Schedule II stimulants for outpatient ADHD. Florida limits NPs to 7-day supplies of Schedule II unless they’re psychiatric nurses working under a psychiatrist (then they can prescribe 30-day supplies). Pennsylvania allows NPs only 72 hours initially, then 30-day refills with physician involvement. Psychiatrists face none of these restrictions.

How much can I earn doing telehealth ADHD medication management?

Insurance reimbursement is approximately $90-$135 per visit depending on visit length and payer (Medicare, commercial, or Medicaid). If you see four patients per hour at an average of $100 per visit, that’s $400/hour gross. Overhead is lower with telehealth (no office rent), so net income can be strong. Exact earnings depend on your patient volume, payer mix, and platform compensation structure.

Do I have to check the prescription monitoring program every time?

State laws vary. New York requires a PDMP check before each Schedule II prescription. Other states require it periodically (every 90 days) or for initial prescriptions. Even if not legally required, checking the PDMP before prescribing stimulants is best practice to identify red flags (overlapping scripts, multiple providers).

How do I handle patients who request early refills or escalating doses?

Use clinical judgment. Legitimate reasons exist (dose adjustment, lost medication), but patterns of early refills, ‘lost’ prescriptions, or dose escalation without symptom improvement are red flags for misuse. Document your decision-making, consider non-stimulant alternatives, increase visit frequency, or require urine drug screening if concerned. You can decline to prescribe if you suspect diversion or misuse.

Can I prescribe ADHD meds to patients in multiple states?

Only if you’re licensed in each state. Telehealth doesn’t waive state licensing requirements. If you’re licensed in New York and Texas, you can see patients in both states via telehealth. If you’re only licensed in New York, you can’t treat a Texas resident even via video. Some physicians join the Interstate Medical Licensure Compact to expedite multi-state licensing.

What happens if the federal telehealth waiver expires?

If the DEA doesn’t extend the waiver or enact a permanent rule, the Ryan Haight Act’s in-person requirement would return. You’d need to see new ADHD patients in person at least once before prescribing Schedule II stimulants via telehealth. Existing patients could continue telehealth follow-ups. Many expect Congress or the DEA to address this before it becomes an issue, but prepare contingency plans (partner with local clinics for in-person exams if needed).

Is telehealth ADHD care as effective as in-person?

Research shows telehealth psychiatry is comparable to in-person care for ADHD medication management. Diagnostic accuracy, treatment adherence, and patient satisfaction are similar. The key is conducting thorough evaluations — using video, validated scales, and collateral information replicates in-office assessment. Telehealth may even improve access for patients who couldn’t otherwise see a specialist.

What’s the risk of regulatory scrutiny for prescribing stimulants online?

The risk exists, especially after high-profile cases of inappropriate prescribing. Protect yourself by following standard of care: document comprehensive evaluations, schedule regular follow-ups, check the PDMP, use clinical judgment on dose escalation, and avoid ‘prescription factory’ practices (e.g., prescribing after a 5-minute chat). State medical boards are more likely to investigate providers with patterns of high-volume, low-documentation prescribing.

The Bottom Line: Telehealth ADHD Prescribing Is Legally and Financially Viable — If You Do It Right

Psychiatrists in 2026 have a rare opportunity. ADHD patient demand is at an all-time high. Telehealth regulations, while uncertain long-term, currently support online prescribing of stimulants. Reimbursement is strong thanks to payment parity. And the provider shortage means you can build a full practice quickly.

But this isn’t a shortcut. Quality matters. Regulatory scrutiny is real. The same clinical rigor you’d apply in an office visit applies via video: thorough evaluations, evidence-based prescribing, regular monitoring, and documentation that demonstrates standard of care.

State laws vary, but psychiatrists have a clear advantage: unrestricted prescriptive authority. Unlike NPs in Texas, Florida, or Pennsylvania, you don’t need a collaborator or face arbitrary quantity limits. You can independently diagnose and treat ADHD patients, which makes you invaluable on telehealth platforms operating in multiple states.

The economics make sense. Instead of gambling thousands per month on marketing with uncertain ROI, platforms like Klarity Health offer a pay-per-appointment model: you’re paid when you see patients, the platform handles patient acquisition, and there’s no upfront cost or monthly subscription gambling. You control your schedule, the platform pre-qualifies patients, and you focus on what you do best — clinical care.

If you’re a board-certified psychiatrist with a DEA registration, licensed in a state with ADHD demand (which is every state), and you want to expand into telehealth, now is the time. The regulatory window is open, patient need is urgent, and platforms are actively recruiting providers.

Ready to join a telehealth platform that removes patient acquisition risk and pays you fairly per visit? Explore Klarity Health’s provider network. No upfront marketing spend, no monthly fees, pre-matched patients, and full telehealth infrastructure included. You prescribe, we handle the rest.

Sources and Citations

All regulatory and clinical information in this guide is current as of February 2026 and verified against official sources. State-specific laws were cross-referenced with state statutes and regulatory body websites. Federal policy reflects DEA and HHS guidance as published through late 2025.

Top 5 Key Sources:

1. U.S. Drug Enforcement Administration (DEA) & HHS Extension Notice (Nov 2024): ‘The Drug Enforcement Administration and the Department of Health and Human Services announced Monday they’re extending pandemic-era rules allowing online prescribing of controlled substances like Adderall through the end of 2025… the third temporary extension of the rules.’ Source: Axios, November 18, 2024. www.axios.com

2. Florida Statutes §456.47 (Telehealth – Controlled Substances for Psychiatric Disorders): Florida law explicitly permits telehealth providers to prescribe Schedule II controlled substances when ‘the controlled substance is prescribed for… a psychiatric disorder.’ This carve-out allows stimulant prescribing for ADHD via telemedicine. Source: Florida Senate, 2023 Statutes. www.flsenate.gov

3. RxAgent ‘NP Prescriptive Authority by State’ (2026 Guide): Comprehensive state-by-state breakdown of Nurse Practitioner prescribing authority and restrictions, including specific rules for Schedule II controlled substances (e.g., Texas NPs cannot prescribe Schedule II outside hospitals; Pennsylvania NPs limited to 72-hour initial prescriptions). Source: RxAgent blog, updated December 28, 2025. rxagent.co

4. Therathink ‘Insurance Reimbursement Rates for Psychiatrists [2026]’: Detailed CPT code reimbursement data for Medicare, Medicaid, and commercial insurance. Medicare pays approximately $89-$95 for 99213 and $125-$136 for 99214; Medicaid roughly $41-$64. Psychiatrists are reimbursed at the highest level among mental health providers. Source: Therathink, 2026 edition. therathink.com

5. Associated Press ‘More Adults Sought Help for ADHD During Pandemic’: Reports that ADHD stimulant prescriptions surged during the pandemic as telehealth lowered barriers to diagnosis and treatment. Cites FDA/JAMA Psychiatry data on prescription trends and medication shortages. Source: AP News, January 10, 2024. apnews.com

Additional Sources:

• Texas SB 2527 Bill Analysis (88th Legislature, 2023): Legislative analysis noting concerns about inappropriate online prescribing of controlled substances and emphasizing standard of care requirements for telemedicine. capitol.texas.gov

• Florida Statutes §464.012 (APRN Prescribing): Details Florida’s 7-day limit on APRN Schedule II prescriptions and the psychiatric nurse exemption allowing 30-day supplies under psychiatrist protocol. www.leg.state.fl.us

• Healing Psychiatry Florida ‘Psychiatrist Shortage by State – 2026 Report’: State-by-state psychiatrist-to-population ratios. Texas (~1:9,327), Florida (~1:8,577), Pennsylvania (~1:4,586),

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the